



[Home](#) / [Investors](#) / [News Releases](#)

Insmed Retains FD and Gibraltar Associates for Investor Relations and Corporate Communications

RICHMOND, Va., Dec 03, 2007 /PRNewswire-FirstCall via COMTEX News Network/ -- Insmed Inc. (Nasdaq: INSM), a biopharmaceutical company, announced today that it has retained FD and Gibraltar Associates to provide investor relations and corporate communications services, respectively. FD and Gibraltar intend to offer an integrated program to highlight Insmed's role as a pioneer and leader in the emerging field of follow-on biologics and to increase the Company's institutional investor visibility.

"With the characterization of our first two follow-on biologics now completed and positioned for clinical studies, Insmed is at the forefront of a rapidly emerging field with significant growth potential," said Geoffrey Allan, CEO of Insmed. "We believe this is the right time to launch a comprehensive communications plan to identify high-quality institutional investors, and successfully position Insmed's investment thesis. Working with FD and Gibraltar provides us with elite talent and expertise in investor and public relations. We are turning to them to help us to tell our story and maximize shareholder value."

"We believe our life sciences expertise and knowledge of the public markets are an excellent strategic fit for Insmed, and we look forward to working with Insmed's management team and Gibraltar Associates," said Jonathan Birt, Managing Director of the Healthcare & Life Sciences practice at FD. "FD has an extensive track record in working with the world's leading scientific and medical companies, and we are pleased to have the opportunity to support Insmed at such an important stage of its development."

"Our experience in repositioning corporate brands, navigating public affairs challenges, and unlocking shareholder value promises to create a successful partnership with Insmed," said Eric Bovim, CEO of Gibraltar Associates. "We look forward to working with Insmed and FD in communicating the substantial market potential for follow-on biologics, and highlighting Insmed's unique position in the industry."

Headquartered in Richmond, Virginia, Insmed is at the forefront of the development of follow-on biologics. The Company has an FDA-approved biologics commercial manufacturing facility in Boulder, Colorado, and has significantly expanded its comprehensive capabilities in the characterization, development and manufacturing of follow-on biologics. Insmed recently completed the characterization of its first two follow-on biologics, INS-19 (Granulocyte Colony Stimulating Factor or G-CSF) and INS-20 (Peg G-CSF), both for the treatment of neutropenia. The Company intends to initiate clinical studies on these product candidates in 2008. Insmed is also continuing to advance its proprietary protein platform into niche markets with unmet needs. Insmed's lead product in this area is IPLEX(TM), which previously received FDA approval for the treatment of severe primary IGF deficiency, and is currently in clinical development for Myotonic Muscular Dystrophy (MMD), ALS (Lou Gehrig's Disease) and HIV-Associated Adipose Redistribution Syndrome (HARS).

About Insmed

Insmed Inc. is a biopharmaceutical company with unique protein process development and manufacturing experience and a proprietary protein platform aimed at niche markets with unmet medical needs. For more information, please visit www.insmed.com.

About FD

As the world's most sought-after business and financial communications consultancy, FD helps the world's leading organizations harness the power of communications to solve critical business challenges that threaten their brand, reputation and valuation. Named PR Week's 2006 "International Consultancy of the Year," FD's 500 professionals advise clients from 17 offices in every major business center in the world. FD is a division of FTI Consulting (NYSE: FCN), a global corporate advisory firm specializing in helping clients overcome complex business challenges in areas such as restructuring, litigation, mergers and acquisitions, regulatory

investigations, and reputation management, among many others. For more information, please visit www.fd.com.

About Gibraltar Associates

Gibraltar Associates is a consultancy specializing in risk and reputation management, public affairs and business development for clients worldwide. Gibraltar Associates blends expertise from diverse consulting genres to offer clients a truly holistic approach to solving challenges confronting the business. Our mission is to provide world-class counsel to clients and implement those ideas to produce a tangible business result. The company is based in Washington, D.C., with an office in Los Angeles. For more information, please visit: www.Gibraltar-llc.com or call 202-879-5808.

Forward-Looking Statements

This release contains forward-looking statements which are made pursuant to provisions of Section 21E of the Securities Exchange Act of 1934. Investors are cautioned that such statements in this release, including statements relating to planned clinical study design, regulatory and business strategies, plans and objectives of management and growth opportunities for existing or proposed products, constitute forward-looking statements which involve risks and uncertainties that could cause actual results to differ materially from those anticipated by the forward-looking statements. The risks and uncertainties include, without limitation, risks that product candidates may fail in the clinic or may not be successfully marketed or manufactured, we may lack financial resources to complete development of product candidates, the FDA may interpret the results of studies differently than us, competing products may be more successful, demand for new pharmaceutical products may decrease, the biopharmaceutical industry may experience negative market trends, our entrance into the follow on biologics market may be unsuccessful, our common stock could be de-listed from the Nasdaq Global Market and other risks and challenges detailed in our filings with the U.S. Securities and Exchange Commission, including our Quarterly Report on Form 10-Q for the quarter ended September 30, 2007. Readers are cautioned not to place undue reliance on any forward-looking statements, which speak only as of the date of this release. We undertake no obligation to publicly release the results of any revisions to these forward-looking statements that may be made to reflect events or circumstances that occur after the date of this release or to reflect the occurrence of unanticipated events.
